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Abstract: Glioblastoma (GBM) is the most aggressive form of brain cancer, with a dismal 
prognosis and extremely low percentage of survivors. Novel therapies are in dire need to 
improve  the  clinical  management  of  these  tumors  and  extend  patient survival.  Genetic 
therapies for GBM have been postulated and attempted for the past twenty years, with 
variable degrees of success in pre-clinical models and clinical trials. Here we review the 
most common approaches to treat GBM by gene therapy, including strategies to deliver 
tumor-suppressor genes, suicide genes, immunomodulatory cytokines to improve immune 
response,  and  conditionally-replicating  oncolytic  viruses.  The  review  focuses  on  the 
strategies used for gene delivery, including the most common and widely used vehicles 
(i.e., replicating and non-replicating viruses) as well as novel therapeutic approaches such 
as stem cell-mediated therapy and nanotechnologies used for gene delivery. We present an 
overview of these strategies, their targets, different advantages, and challenges for success. 
Finally, we discuss the potential of gene therapy-based strategies to effectively attack such 
a complex genetic target as GBM, alone or in combination with conventional therapy.  
Keywords:  gene  therapy;  oncolytic  virus;  stem  cells;  nanotechnology;  gene  transfer; 
glioma invasion; suicide gene; immunomodulation 
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1. Introduction 
Glioblastoma (GBM) is the most aggressive tumor of the Central Nervous System (CNS) and its 
prognosis is one of the worst among all cancer types. Although the number of GBM cases is small 
compared to other solid tumors, population statistics still reveal a dim picture after years of research 
and improvement in the clinical management of this disease [1]. Of the approximately 13,000 new patients 
diagnosed with GBM in the US every year, almost 50% of the patients die within one year and 90% 
within three years following diagnosis [2], causing more years of life lost than most types of cancer [3].  
GBM is therefore considered a fatal malignancy, incurable by conventional therapeutic strategies [4]. 
A major factor that contributes to the dismal prognosis of GBM is the physical and physiological 
isolation of these tumors within the CNS, which makes difficult the delivery of chemotherapeutics. In 
addition,  the  CNS  is  largely  regarded  as  an  immune  sanctuary  protected  from  systemic  immune 
responses, therefore facilitating immune evasion of tumor cells and limiting the efficacy of systemic 
immune-boosting approaches. A third and critical factor that makes these tumors extremely difficult to 
eradicate is the highly invasive nature of GBM cells, which disperse along blood vessels and white 
matter, resulting in a disseminated disease that is impossible to completely resect [4]. Finally, the 
presence  of a disseminated tumor  stem-like cell population that supports tumor self-renewal  and  is 
particularly resistant to chemo- and radio-therapy, is another major factor underlying tumor recurrence 
and poor long-term survival [5].  
Given the resistance of these tumors to conventional therapeutic approaches there is an urgent need 
to develop alternative strategies to complement or improve current approaches and improve long-term 
patient  survival.  Strategies  under  development  include  novel  adjuvant  chemotherapeutics  to  be 
combined with standard care, as well as novel molecularly-targeted approaches against the tumor and 
its  microenvironment.  In  this  review  we  will  focus  on  a  host  of  molecularly-targeted  approaches 
collectively aggregated under the concept of gene therapy. 
Gene  ―therapy‖  as  the  possibility  of  selecting  the  genetic  information  of  organisms  was  first 
mentioned even before the identification of DNA as genetic material [6], but the formal concept of 
gene  therapy  as  horizontal  transfer  of  genetic  material  with  the  potential  to  treat  diseases  only 
solidified in the early 1970s [7], when technological advances allowed researchers to deliver tailored 
genetic material to mammalian cells. ―Strict‖ gene therapy is based on the ability to replace a defective 
gene function through delivery and integration of the functional version of the gene. Therefore, gene 
therapy strategies have largely been developed for genetic diseases with clear dependency on a single 
gene deficiency [8], such as recessive enzymatic deficiencies and blood disorders.  
Despite being a genetic disease, the possibility of applying strict gene therapy for cancer is less 
straightforward since tumors develop through multiple known and unknown genetic abnormalities. 
Moreover, the accumulation of mutations and evolution of the tumor’s genetic makeup during malignant 
progression  make  cancers  a  genetic  moving  target  that  would  defeat  the  single  gene-replacement 
approach.  Therefore,  the  concept  of  gene  therapy  for  cancer  has  been  widened  to  encompass  the 
general  delivery  of  therapeutic  genetic  material  to  the  tumor,  to  kill  cancer  cells  or  enhance  the 
immune response against them. 
Strategies  for  gene  therapy  of  cancer  in  general,  and  gliomas  in  particular,  have  been  in 
development for the past twenty years, with a strong record of success in pre-clinical models and an Cancers 2013, 5   1273 
 
 
increasing number of models reaching clinical trials [9] (see Table 1 for a summary of active trials). 
Major approaches employed for gene therapy of GBM have included: (1) delivery of suicide genes to 
convert prodrugs in the tumor and achieve tumor cell death; (2) delivery of cytokine genes to activate 
and attract immune cells against the tumor; (3) delivery of tumor-suppressor genes to reprogram tumor 
cells into apoptosis; and (4) delivery of conditionally-replicating viruses to specifically lyse tumor cells 
while sparing normal tissue. Carriers of genetic material have usually been viruses, but alternative 
vehicles such as stem cells, nanoparticles and liposomes, have also been extensively developed and 
reached the clinical stage. The following sections will describe these approaches in detail, comparing 
the advantages and specific challenges faced by each one. A summary of these strategies and examples 
of representative genes employed are shown in Figure 1.  
Table  1.  Active  clinical  trials  for  gene  therapy  of  GBM.  Clinical  trials  listed  in  this  
table  are  registered  with  active  status  (open,  recruiting  or  ongoing)  as  of  May  2013. 
Source: US National Institutes of Health [10] and Journal of Gene Medicine [11]. 
Country/Identifier  Model  Strategy/goals  Carrier  Phase 
US/NCT00589875  AdV-TK  Suicide gene  non-replicating virus  IIa 
China/CT00870181  AdV-TK  Suicide gene  non-replicating virus  II 
US/NCT00634231  AdV-TK (plus radiotherapy)  Suicide gene  non-replicating virus  I 
US/NCT00751270  AdV-TK (plus radiotherapy)  Suicide gene  non-replicating virus  Ib * 
US/NCT00589875  AdV-TK (plus radiotherapy)  Suicide gene  non-replicating virus  IIa * 
US/NCT01811992 
(1) AdV-hCMV-TK and  
(2) AdV-hCMV-Flt3L 
(1) Suicide gene 
(2) Immune stimulation 
non-replicating virus  I 
US/NCT01156584 
retroviral vector (Toca-511) 
carrying CDA 
Suicide gene and viral 
oncolysis 
replicating virus  I/II 
US/NCT01174537  New Castle Disease Virus  Viral oncolysis  replicating virus  I/II 
US/NCT01301430 
H-1 parvovirus  
(ParvOryx-01) 
Viral oncolysis  replicating virus  I/II 
US/NCT01491893 
engineered chimeric 
poliovirus (PVS-RIPO) 
Viral oncolysis and 
immune stimulation 
replicating virus  I 
US/NCT00390299 
Engineered measles virus 
(MV-CEA) 
Viral oncolysis and 
immune activation 
replicating virus  I 
US/NCT01582516 
AdV-Delta-24-RGD 
delivered via CED 
Viral oncolysis  replicating virus  I/II 
US/NCT00805376  AdV-Delta-24-RGD-4C  Viral oncolysis  replicating virus  I 
UK/UK-0050  HSV 1716  Viral oncolysis  replicating virus  II 
US/NCT01172964  stem cells carrying CDA  Suicide gene  neural stem cells  Pilot 
Abbreviations:  AdV,  adenovirus;  CDA,  cytosine  deaminase;  CED,  convection-enhanced  delivery;  CMV, 
cytomegalovirus promoter; Flt3L, FMS-like tyrosine kinase 3 ligand; TK, thymidine kinase; *: E.A.C. is 
currently involved in these two active (non-recruiting) clinical trials. 
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Figure 1. Different strategies for gene therapy of GBM. (A) Suicide genes: GBM cells 
receive the suicide gene by local injection of a carrier, together with systemic delivery of a 
prodrug (1). The suicide gene converts the prodrug into a cytotoxic product (2) that kills 
the recipient cell and non-transduced bystander tumor cells (3); (B) Immune activation: 
The gene for an immunomodulatory cytokine is delivered to the tumor cells using several 
possible  vehicles  with  tumor  tropism  (1),  including  viruses  or  stem  cells.  Cytokine 
expression  increases  tumor  cell  apoptosis  (2)  and  activates  immune  cells  such  as 
macrophages, natural killer cells or T-cell lymphocytes (3); (C) Oncolysis: The tumor is 
infected with conditionally-replicating oncolytic viruses (1) that lyse the tumor cells (2–3) 
while sparing normal ones; (D) Reprogramming: Tumors receive the functional copy of a 
tumor suppressor gene (1), which subsequently induces cell cycle arrest or apoptosis (2).  
 Cancers 2013, 5   1275 
 
 
2. Virus-Based Gene Therapy of GBM  
Viruses targeting mammalian cells have evolved as effective vehicles for horizontal gene transfer 
and have therefore been the preferred approach for gene therapy since its beginnings [7]. Moreover, 
the specific neurotropism of certain  herpesviruses, adenoviruses and paramyxoviruses  [12–16] has 
made them particularly valuable to target cells of the neural lineage, including malignant brain tumor 
cells. The first attempt to treat gliomas with a non-engineered virus was an unsuccessful study using 
attenuated  mumps  virus,  conducted  in  1982  [17].  A  decade  later,  two  improved  strategies  using 
engineered  viruses  were  described  almost  simultaneously:  the  use  of  transduced  cells  delivering 
engineered  retroviruses  into  the  tumor  stroma  [18,19],  and  the  first  use  of  an  engineered  Herpes 
simplex virus (HSV) for selective replication in glioma cells [20]. This research marked the beginning 
of two of the major strategies used in glioma virotherapy: (a) targeting the tumor with replication-deficient 
viruses carrying conditionally-expressing suicide genes; and (b) using tumor-specific, replication-competent 
oncolytic viruses. The following sections describe the major strategies that have been employed for 
GBM gene therapy using viruses and their current pre-clinical and clinical status.  
2.1. Viral Delivery of Suicide Genes 
Systemic chemotherapy of tumor cells is usually limited by toxic side effects caused on dividing 
normal cells. Suicide gene therapy was envisioned as a way to overcome this limitation, and is based on 
the systemic delivery of an inactive prodrug together with tumor-specific expression of a drug-activating 
enzyme (the suicide gene) [21,22]. Suicide genes are usually absent or expressed at very low levels in 
mammalian cells [23] and are therefore delivered using a viral transduction system [9]. 
The best studied suicide gene is the HSV-derived enzyme Thymidine Kinase (HSV-TK) [9,24,25]. 
This enzyme catalyzes the phosphorylation of cytotoxic nucleoside analogues that can be incorporated 
into the DNA of actively proliferating cells, disrupting DNA replication and halting cell division. 
Since the prodrug nucleosides are poor substrates for mammalian TK, the toxic effect can be restricted 
to actively dividing cells that have been transduced with HSV-TK using non-replicating herpesvirus or 
adenovirus [9,23]. This strategy was first used by Ezzedine and colleagues in 1991 to demonstrate the 
selectivity and efficacy of HSV-TK to kill subcutaneously-implanted glioma cells upon administration 
of the prodrug ganciclovir [26]. Improvements of this strategy have included the use of different drug 
formulations  to  enable  sustained  intratumoral  drug  delivery  [27]  and  the  use  of  mutant  HSV-TK 
versions that confer increased sensitivity to the antiviral prodrugs [25,28]. 
An  added  advantage  of  suicide  gene  therapy  is  the  spread  of  cytotoxicity  from  the  originally 
infected cells to neighboring neoplastic, non-infected cells, an effect known as bystander cytotoxic 
effect  [22,29,30].  In  the  case  of  TK,  however,  the  bystander  effect  is  somewhat  limited  because 
phosphorylated nucleoside analogues do not cross the cell membrane. Instead, they must be transferred 
to the neighboring cells via gap-junctions or by release of apoptotic vesicles from the infected, dying 
cell [31–33].  
In spite of the initial promise of suicide gene therapy for glioma, further evidence suggested that 
even HSV-TK expressing cells could become resistant to the prodrugs, therefore requiring combination 
of  this  molecularly-directed  gene  therapy  with  conventional  chemo-radiotherapy  [25,28,34–36].  Cancers 2013, 5   1276 
 
 
There has also been concern about possible toxic effects, poor rate of delivery of HSV-TK to the tumor 
cells  [37],  and  immune  response  against  the  delivery  vehicle.  For  example,  non-human  primates 
treated with adenovirus-delivered HSV-TK showed dose-dependent toxicity and developed antibodies 
against the viral particles [38]. Chronic inflammatory symptoms (including macrophage activation and 
lymphocyte infiltration) were also observed in the brain of long-term surviving rats that had been 
implanted with intracranial gliomas and treated with adenovirus-delivered HSV-TK [39]. Despite these 
caveats, viral-delivered HSV-TK has proven to be a safe strategy in multiple phase I and II clinical 
trials [40–42] and continues to be the most common suicide gene approach in active trials (see Table 1 
for active clinical trials). Side effects have been fairly minimal and the major limiting factor has not 
been toxicity but lack of significant improvement in efficacy against placebo. This was demonstrated 
in a large, multicenter, phase III clinical trial for HSV-TK (GLI328 International Study Group) that 
employed retrovirus-producing cells to deliver HSV-TK gene therapy in patients with newly-diagnosed 
GBM [37]. The trial reported a good safety profile for this adjuvant treatment, although there were no 
significant  improvements  in  progression-free  or  overall  survival.  This  lack  of  effect  was  largely 
attributed to poor distribution of the carrier and limited delivery of HSV-TK into the tumor.  
Another  widely  studied  suicide  gene  is  the  bacterial  enzyme  Cytosine  Deaminase  (CDA),  
which converts the prodrug 5-fluorocytosine to the toxic compound 5-fluorouracil (5-FU). 5-FU can  
be  further  converted  to  5-fluorouracil  triphosphate,  which  interferes  with  RNA  processing,  or  
5-fluorouridine-5'-monophosphate, which irreversibly inhibits DNA synthesis [23]. Importantly, 5-FU 
can  diffuse  to  neighboring cells  and achieves bystander cytotoxic  effect that does  not  require the 
presence of physical cell-cell contacts [21,43]. Further enhancement of cytotoxicity has been achieved 
by using an engineered bacterial CDA (bCDA-Asp
314Ala) with increased affinity for 5-fluorocytosine. 
Combination of this recombinant CDA with radiotherapy has shown significant tumor cell killing and 
delayed tumor growth in xenograft models of glioma [23]. Adenovirus-delivered CDA has also been 
combined with a second enzyme,  Uracil Phosphoribosyl Transferase (UPRT), which catalyzes the 
conversion  of  5-FU  into  5-fluorourydine-5'-monophosphate.  Simultaneous  expression  of  CDA  and 
UPRT genes has shown cooperative antitumor effects [41]. Interestingly, the sensitivity of glioma cells 
to the combination of CDA and UPRT plus systemic 5-fluorocytosine seemed to be p53-dependent [44], 
suggesting that p53 status could be used as stratification criteria for this treatment. Viral-delivered, 
CDA-based therapy has reached the clinical stage and a non-lytic, replicating retroviral vector (Toca-
511) [45] is currently being tested in a phase I/II clinical trial to deliver the enzyme in combination 
with 5-fluorocytosine in patients with recurrent high-grade glioma (NIH trial NCT01156584, Table 1).  
A third example of nucleoside-modifying suicide gene therapy is the use of E. coli-derived Purine 
Nucleoside  Phosphorylase  (PNP),  which  can  convert  non-toxic  adenosine  ribonucleosides  (e.g., 
fludarabine)  into  toxic  adenine  analogs  (2-fluoroadenine)  that  disrupt  RNA  processing.  These 
metabolites can diffuse to neighboring cells, resulting in robust bystander effect in proliferating and 
non-proliferating cells [46,47]. Retrovirus-carried PNP has been shown to integrate in the host cell 
DNA, leading to long-term effect of this treatment in vivo [47]. An important development of this 
approach was the combination of herpesvirus-delivered PNP with antibiotics to remove intestinal flora 
that could convert the prodrug outside the tumor. This approach allowed the use of lower doses of the 
cytotoxic agent, enhancing chemoprotection and efficacy in a mouse model of glioma [48].  Cancers 2013, 5   1277 
 
 
Nucleic acid-targeting gene therapies have also used transgenes coding for enzymes that generate 
DNA-alkylating compounds. This strategy has a considerable advantage because cytotoxicity does not 
depend  on  DNA  replication  or  RNA  expression,  therefore  killing  both  proliferating  as  well  as 
quiescent glioma cells. An example of pro-alkylating suicide gene that has been tested in several solid 
tumor models is the bacterial enzyme carboxypeptidase G2 (CPG2). When combined with nitrogen 
mustards prodrugs (such as 4-[(2-chloroethyl)(2-mesyloxyethyl)amino]benzoyl-L-glutamic acid (CMDA) 
or  ZD2767P),  CPG2  yields  mustard-like  compounds  that  crosslink  DNA  [49].  This  conversion  is 
specific to CPG2, which has no mammalian homologues, therefore preventing non-specific generation 
of highly toxic alkylating compounds in off-target tissues. Engineering of this enzyme for cell-surface 
expression has been used to enhance the bystander effect of prodrugs that cross the cell membrane 
poorly and do not reach therapeutic effect with intracellular CPG2 [50]. Although CPG2 has not been 
tested in gliomas in vivo, it has been delivered to cultured glioma cells using replication-deficient 
adenoviruses and shown cytotoxicity comparable or higher than HSV-TK in the same cells [51]. 
One extensively studied pro-alkylating suicide gene therapy has used cytochrome P450 (CYP2B1 
gene), the only example of a mammalian-derived suicide gene. This cytochrome can hydroxylate the 
immunomodulatory  prodrug  cyclophosphamide  (CPA),  generating  an  alkylating  phosphoramide 
mustard. The first demonstration of this strategy for gliomas in vivo used fibroblasts transduced with a 
replicating retrovirus carrying CYP2B1, which were injected intratumorally in mice carrying intracranial 
GBM xenografts [52]. Following intrathecal administration of CPA, this study demonstrated partial 
regression of the intracranial tumor mass and limited or absent tumor dispersion to the meningeal 
space.  Further  development  of  this  strategy  placed  the  CYP2B1  gene  in  a  replicating  HSV  (see 
description of oncolytic HSV in Section 2.5), showing strong antitumor effect when CPA chemotherapy 
was  combined  with  HSV-mediated  tumor  oncolysis  [53].  A  significant  advantage  of  CPA  is  the 
inhibitory effect of this drug on the innate immune activity against HSV, therefore reducing viral 
clearance and enhancing both gene delivery and viral oncolysis [54].  
Finally, it should be noted that the concept of suicide genes can be expanded to include additional 
examples of cytotoxic genes as long as they are specifically delivered to and active in the target tumor 
cells. One example is the potent Pseudomonas exotoxin A, a cytotoxin produced by Pseudomonas 
aeruginosa  that  disrupts  protein  synthesis.  A  truncated  form  of  this  toxin  conjugated  to  mutated 
interleukin IL-13 (mhIL-13-PE, marketed under the name Cintredekin Besudotox) specifically binds 
and kills glioma cells while sparing normal neural cells that lack the glioma-specific receptor for the 
interleukin  (IL13Rα2)  [55].  In  an  elegant  development  of  this  strategy,  an  adenoviral  vector  was 
developed for conditional expression of mhIL-13-PE in transduced glioma cells [56]. The vector also 
expressed IL-4 to saturate the normal receptor of IL-13 (IL4R/IL13R), therefore preventing binding of 
the  chimeric  toxin  to  normal  neural  cells  and  achieving  specific  cytotoxicity.  Inoculation  of  this  
virus in multiple models of intracranial glioma using athymic and immunocompetent mice resulted  
in  significant  tumor  toxicity  and  increased  animal  survival  with  high  proportion  of  long-term  
survivors [56].  
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2.2. Viral Delivery of Tumor-Suppressor Genes 
Tumor  suppressor  genes  are  major  regulators  of  DNA  repair,  cell  proliferation,  and  apoptosis. 
Deletions and inactivating mutations in those genes are common in all cancers, including gliomas. In 
particular, mutations in three pathways containing tumor suppressors are commonly associated with 
high-grade human gliomas: p53/MDM2, p16/Rb, and PTEN [57]. Based on this feature of brain tumor 
biology, viral strategies have been designed in an attempt to reprogram tumor cells by restoring tumor 
suppressor activity in cells carrying inactivating mutations in those genes.  
p53 is considered one of the most critical mediators of growth arrest and apoptosis in response to 
DNA damage, hypoxia, and growth factor withdrawal. This is one of the most frequently mutated 
genes in gliomas, being inactivated in  about 30%  of primary and 65% of secondary GBMs [58]. 
Tumor suppressor therapy using p53 in glioma cells was first attempted by delivering this gene, under 
control of the potent CMV promoter, using non-replicating adenovirus serotype 5 (Ad5CMV-p53). 
Restoration of the functional gene induced robust apoptosis of the infected cells in vitro and reduced 
tumorigenesis  in  vivo  [59].  However,  inoculation  of  the  same  vector  in  GBM-bearing  mice  was 
insufficient to reduce intracranial tumor growth [60], possibly due to poor gene transfer in established 
tumor tissue. Interestingly, adenoviral transduction of p53 into wild type p53-bearing glioma cells has 
also shown marginal [59–61] to robust [62] inhibition of cell proliferation and induction of apoptosis, 
indicating that these effects are not solely dependent on the restoration of a functional copy of p53.  
Limitations of tumor suppressor-based gene therapy have included poor gene transfer as mentioned, 
lack of bystander effect, and potential resistance arising from the inherent genetic heterogeneity within 
GBM.  However,  transduction  of  tumor  suppressor  genes  such  as  p53  may  present  an  excellent 
opportunity  for  combinatorial  therapy  since  they  could  re-sensitize  the  cells  to  radiation  and 
chemotherapy  [59,61,63,64]  or  reduce  immune  evasion  when  combined  with  immune-boosting 
strategies [65]. Successful pre-clinical results with p53-restoration led to a phase I clinical trial of 
Ad5CMV-p53 (INGN 201) for recurrent malignant glioma, involving injection of the virus pre- and 
post-resection. Exogenous p53 protein was found in the nuclei of tumor cells in all patients treated 
with this strategy, although transduced cells were found only within a short distance from the injection 
site. Adverse events were minimal and the trial tested doses up to 3 ×  10
12 plaque-forming units (p.f.u.) 
without reaching maximum tolerable dose [66]. 
p16
INK4A  is  another major  tumor  suppressor that  causes  cell cycle arrest  at  the  G1-S transition  
point  by  maintaining  hypo-phosphorylated  status  in  the  Retinoblastoma  protein  (Rb)  [59,60]. 
Adenoviral-mediated restoration of p16 in GBM cells induced, as expected, tumor cell cycle arrest in 
G1-S phase [67,68]. Surprisingly, this overexpression of p16 also caused an unexpected reduction in 
GBM  cell  invasion,  resulting  from decreased activity of matrix  metalloprotease 2.  This  important  
anti-invasive effect is remarkable since it was not observed after restoration of the tumor suppressor 
p21/WAF, which prevents G1-S transition by a molecular mechanism similar to p16 [67].  
The third major tumor suppressor regulating glioma growth and invasion is the Phosphatase and 
Tensin Homologue (PTEN), which is lost, mutated or inactivated in 40%–50% of all gliomas (~25% of 
primary  GBMs)  [58],  resulting  in  high  levels  of  dys-regulated  PI3K  activity  and  downstream  
signaling [69]. Adenoviral re-expression of PTEN in GBM cells inhibited Akt kinase activity, leading 
to tumor cell apoptosis [70]. Infection with this virus was also shown to decrease metalloprotease Cancers 2013, 5   1279 
 
 
expression and  glioma  cell  invasion  in  vitro [71].  When  tested in  GBM-bearing  mice,  adenoviral 
restoration  of  PTEN  has  shown  important  effects  on  the  tumor  microenvironment,  inducing  an  
anti-angiogenic response even in presence of pro-angiogenic stimuli such as loss of p53 or presence of 
constitutive EGFR activity [72].  
Another important  example of viral-delivered tumor suppressor strategy has been demonstrated 
with p27, an inhibitor of Rb phosphorylation that arrests the cell cycle in G1. p27 levels are regulated 
by complex feedback loops involving phosphorylation of this protein in Thr
187 and further proteasomal 
degradation [73]. p27 activity was restored in GBM cell lines and GBM-derived primary cells using 
adenovirus to carry either wild type (Ad-p27wt) or a degradation-resistant Thr
187-mutant (Ad-p27mt, 
Thr
187Ala). In all cases, recovery of functional p27 promoted Rb dephosphorylation, apoptosis, and 
suppression of tumor growth [68]. Interestingly, while p27wt arrested the cell cycle in G1-S transition 
as expected, p27mt did so at the G2-M checkpoint by undefined mechanisms that were not observed in 
other cell types. Additional studies using adenoviral-restored p27 have demonstrated that this tumor 
suppressor reduces GBM growth in vivo as well as local invasion and tumor-induced neo-angiogenesis, 
with these effects being caused by a cytoskeletal anti-migratory effect of p27 both in GBM cells and 
tumor-associated endothelial cells [74].  
2.3. Viral Delivery of Immunomodulatory Genes 
The CNS is relatively isolated from systemic immune responses and is therefore difficult to induce 
the  immune  system  to  mount  an  effective  local  anti-tumor  response  against  gliomas  [42].  This 
difficulty is increased by the ability of glioma cells to suppress and effectively evade cellular immune 
responses  [9].  In  order  to  promote  effective  immunotherapy  against  glioma,  viruses  have  been 
engineered for targeted delivery and expression of cytokines that activate and recruit immune effectors 
to the tumor.  
An  excellent  example  of  this  strategy  was  the  early  use  of  a  replication-deficient  adenovirus 
carrying the gene for the potent immune-boosting cytokine interferon beta (IFN-beta) under control of 
the  CMV  promoter  [75,76].  Using  this  vector,  IFN-beta  was  expressed  in  pre-established, 
subcutaneous gliomas in nude mice, resulting in enhanced immune cellular response against the tumor 
(lymphocyte  infiltration),  tumor  regression, and  significantly  prolonged  animal  survival  [76].  This 
strategy reached a phase I clinical trial for recurrent malignant glioma, where an IFN-beta-expressing, 
non-replicating adenoviral vector was stereotactically injected in the tumor before surgical resection [77]. 
The trial demonstrated that the virus inoculation was safe and well tolerated, while analysis of the 
resected tumors demonstrated dose-dependent induction of local inflammation and tumor necrosis. 
Using  recombinant  parvoviruses,  another  immunomodulatory  strategy  was  attempted  by 
simultaneous delivery of IFN-gamma-inducible protein 10 (CXCL10) and TNF-alpha in a syngeneic 
mouse model of GBM [78]. Results showed synergistic activity of both vectors and complete regression 
of tumors generated from cells that had been transduced with both cytokines before implantation. 
Multiple  mechanisms  were  proposed  to  contribute  to  this  synergy,  including  CXCL10-mediated 
recruitment of activated T and NK lymphocytes to the tumor, inhibition of tumor angiogenesis by 
CXCL10, and TNF-alpha-mediated tumor necrosis and maturation of dendritic cells. Despite these Cancers 2013, 5   1280 
 
 
exciting results, the effect of the viruses in naï ve pre-established tumors was marginal, resulting in 
delayed tumor growth but no regression [78]. 
Viral-mediated delivery of other interleukins has not been as extensively exploited in GBM as  
in  other  cancers,  but  work  in  this  direction  has  definitely  shown  therapeutically  relevant  results.  
Non-replicating  adenoviral-associated  virus  (AAV)  and  replicating  HSV  have  been  employed  to 
deliver IL-12 in experimental models of GBM [79–81], resulting in local immune mechanisms such as 
increased IFN-gamma expression, microglial activation, and recruitment of T and NK lymphocytes, 
with a significant antitumor effect.  
2.4. Viral Delivery of Genes That Modify the Tumor Stroma  
The gene-delivery strategies described in the previous sections (as well as viral-mediated oncolysis, 
in the following section) target specifically the tumor cells for immediate cell death. Additional effects 
such as reduced tumor vascularization and invasion may be observed (and welcomed) but are not 
usually part of the design rationale. However, viruses can also be engineered to deliver genes that 
specifically  affect  the  tumor  microenvironment.  Two  clear  examples  of  this  strategy  are  viruses 
carrying anti-angiogenic genes or genes that remodel the tumor extracellular matrix (as illustrated in 
Figure 2).  
Initial  attempts  to  specifically  inhibit  glioma  angiogenesis  with  gene  therapy  involved  the 
intratumoral injection of retrovirus and AAV carrying the antiangiogenic factor angiostatin [82,83]. A 
subsequent  study,  using  systemic  instead  of  local  delivery,  followed  a  similar  approach  with 
adenoviral-delivered endostatin [84]. In all cases tumor vascularization was significantly inhibited and 
tumor growth was reduced more effectively than with the parental viruses. A more recent approach has 
combined anti-angiogenesis with viral oncolysis using conditionally-replicating oncolytic HSV (see 
details of this virus in the following section). Two oncolytic HSVs were engineered to express the  
anti-angiogenic protein vasculostatin under control of the promoter for the early viral gene IE4/5 [85,86]. 
Secretion of vasculostatin was detected a few hours after infection of glioma cells and results in vivo 
with both viruses showed remarkable reduction in microvessel density, tumor perfusion, and overall 
tumor progression. Coupled with their oncolytic ability, these antiangiogenic viruses offered significantly 
better antitumor efficacy when compared with their parental HSV strain.  
Delivery of genes that can remodel the tumor extracellular matrix (ECM) has been rarely attempted, 
despite  the  fact  that  this  matrix  is  the  most  immediate  physical  barrier  to  viral  dispersion  and  a 
significant factor that limits viral effects to short distances from the inoculation site  [87]. Indeed,  
pre-injection of proteases that can degrade tumor ECM proteins enhances subsequent viral spread and 
infection [88]. Following this rationale, a conditionally-replicating oncolytic HSV was engineered to 
express the bacterial enzyme chondroitinase ABC-I, which degrades major components of the glioma 
ECM such as hyaluronan and chondroitin sulfate proteoglycans [89]. The resulting virus demonstrated 
increased efficacy against the tumor compared to parental HSV and, as expected, dispersed farther 
away  from  the  sites  of  inoculation.  Local  degradation  of  ECM  was  also  demonstrated,  which, 
importantly, did not enhance the invasive ability of the remaining tumor cells.  
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Figure  2. Strategies targeting the GBM  microenvironment. To enhance viral oncolysis 
conditionally-replicating  oncolytic  viruses  may  also  carry  genes  that  modify  the  tumor 
microenvironment.  (A)  Anti-angiogenic  strategies:  viruses  carry  anti-angiogenic  factors 
that reduce vascular support of the spared tumor not reached by oncolysis; (B) Anti-ECM 
strategies: viruses carry enzymes that degrade ECM components, increasing dispersion of 
viral particles and oncolytic efficacy.  
 
2.5. Replication-Competent Oncolytic Viruses 
Oncolytic virotherapy (OV) can be considered a gene therapy approach where the whole virus 
becomes the genetic payload. OV utilizes replication-competent viruses that can infect and lyse tumor 
cells, with or without concomitant gene transfer [9,90,91]. OV strategies exploit two major properties 
of the viruses used as vehicles/lytic agents: Tropism towards cells of neural lineage/brain tumor cells, 
and the ability to specifically replicate in tumor cells with altered signaling pathways while sparing 
normal  cells  [90,92–94].  Oncolytic  HSV,  conditionally-replicating  adenovirus  (CRAd),  reovirus, 
poliovirus, engineered retroviruses, Newcastle Disease virus and measles virus have been evaluated for 
OV therapy of GBM [95]. 
HSV  is  an  enveloped  DNA  virus  with  wide  tropism  that  replicates  in  dividing  and  
non-dividing  cells  [9,91].  This  virus  establishes  latent  infection  in  post-mitotic  neurons  and  is 
especially  suitable  for  therapeutic  strategies  in  the  CNS.  To  reduce  neurovirulence,  engineered 
versions have been attenuated through deletions in genes necessary for viral replication in normal cells, Cancers 2013, 5   1282 
 
 
such as the ribonucleotide reductase ICP6 (UL39) and the protein synthesis promoting factor ICP34.5 
(γ34.5) [96]. Two recombinant oncolytic HSV have reached clinical trials for recurrent high-grade 
glioma: The virus HSV G207 (with an inactivating insertion in ICP6 and deletions in both copies  
of  γ34.5)  was  tested  in  a  phase  I  clinical  trial  where  no  dose-limiting  toxicity  was  observed  up  
to  the maximum tested dose  of  3  ×  10
9  p.f.u.  The study reported  eight  patients (out of 21) with 
radiographic/histologic response to the treatment and two long-term survivors [97]. A further phase Ib 
trial demonstrated the safety of multiple dose delivery of the same virus, including inoculation both in 
the pre-resected tumor and the post-resection cavity [98]. A similar virus, HSV1716 (deleted in both 
copies of γ34.5) reached phase II trial for intratumoral delivery. HSV1716 treatment showed positive 
response in three out of twelve patients and did not cause toxicity even when patients developed 
antibodies against the virus [99,100]. A disadvantage of these models is the required deletion of viral 
genes (γ34.5), which attenuates viral replication and limits the virus efficacy [101]. A new generation 
of oncolytic HSVs is therefore being studied in pre-clinical models and prepared for clinical trials.  
A major modification that enhances the efficacy of these viruses is the conditional re-expression of 
viral genes under promoters that are overexpressed in brain tumor cells compared to normal cells, such 
as Nestin, GFAP, or survivin [102–104]. 
CRAds with deleted viral genes have been employed as alternative to oncolytic HSV. Adenoviruses 
are non-enveloped DNA viruses that infect proliferating and quiescent cells and can integrate, with low 
frequency, into a defined region of the host genome [9,91]. Two extensively studied CRAds in glioma 
are ONYX-015 and Ad5Delta24, both of which target cells with dys-regulated signaling pathways. 
ONYX-015 has a deletion in the gene coding for the viral protein E1B that binds and inactivates p53. 
Due to this deficiency, the virus was originally expected to replicate selectively in p53-deficient cells 
(i.e.,  tumor  cells)  [105],  although  it  was  later  shown  that  its  oncolytic  activity  in  gliomas  was 
independent of p53 status and even increased in wild-type p53 glioma xenografts [106]. ONYX-015 
was tested in a phase I trial for recurrent malignant gliomas, being injected only in the post-resection 
cavity [107]. Although the study could not demonstrate a significant antitumor efficacy, it showed 
absence  of  serious  adverse  effects  and  good  tolerance  to  the  virus,  without  reaching  maximum 
tolerable dose even at 10
10 p.f.u.  
Similarly  to  ONYX-015,  Ad5Delta24  has  a  genetic  deletion  for  the  viral  protein  E1A,  which 
inactivates the Rb tumor suppressor. Ad5Delta24 therefore replicates in glioma cells with a deficient 
Rb pathway, causing significant growth inhibition of xenografted tumors in mice [108]. This virus was 
further engineered by introducing the integrin-binding RGD motif in the knob domain of the viral fiber 
protein (Ad5Delta24-RGD) [109], which enhanced the specific targeting of tumor cells and increased 
oncolytic  efficacy  against  gliomas  [110].  Ad5Delta24-RGD  is  currently  being  tested  in  a  phase  I 
clinical trial for recurrent malignant glioma (NIH trial NCT00805376, Table 1) [111].  
A novel CRAd that has been recently developed replaces the strategy of viral gene deletion by  
using instead the promoter of a gene highly expressed in glioma cells (survivin) to drive the expression 
of E1A [112]. This virus (CRAd-survivin-pK7) has in addition a poly-lysine sequence added to the 
fiber knob, which enhances the binding to cell surface proteoglycans and increases viral entry and  
anti-tumoral efficacy against differentiated as well as stem-like glioma cells [112,113].  
In addition to the extensively used HSV and CRAds, other viruses have been engineered for OV of 
glioma, including measles, vaccinia, rhabdoviruses and polioviruses [114,115]. Of these, the measles Cancers 2013, 5   1283 
 
 
paramyxovirus (MV, attenuated Edmonston strain) was the earliest to be considered as a potential 
oncolytic  agent  since  initial  reports  in  the  1970s  suggested  that  measles  infection  was  associated  
with regression of lymphoma and leukemia [116,117]. MV targets cells that express the membrane 
receptors  CD46  and  Signaling  Lymphocyte  Activating  Molecule  (SLAM),  inducing  the  formation  
of  multinucleated  syncytia  followed  by  apoptosis.  MV  variants  have  been  engineered  to  express  
IL-13  [118]  or  a single-chain antibody against the vIII deletion variant  of EGFR  [119], therefore  
re-targeting the viruses against proteins highly expressed on the surface of glioma cells and increasing 
their oncolytic efficacy. Additional engineering of MV to express the circulating carcinogenic embryonic 
antigen  (MV-CEA)  has  been  used  to  monitor  the  course  and  maintenance  of  MV  infection  [120]. 
Toxicological data in macaques has shown absence of neurotoxicity of MV-CEA [121] and supported 
an ongoing phase I clinical trial (NIH trial NCT00390299, Table 1). Recent data has also shown that 
MV  is  highly  effective  against  glioma-derived  stem-like  cells  [122],  which  makes  it  an  attractive 
approach against this highly resistant population of tumor cells. 
2.6. Advantages and Challenges of Viral-Based Gene Therapy 
Having evolved for horizontal gene transfer, viruses are the most efficient carrier system to deliver 
genes  to  tumor  cells.  Additional  modifications  described  in  this  review,  such  as  re-targeting  and 
conditional replication have considerably improved the specificity and efficacy of viral vectors, many 
of which have reached clinical trials for GBM. Moreover, compared to other particle-like carriers  
(see Sections 4.1–4.3 on nanotechnology), viruses induce robust bystander cytotoxic effect, attract 
cellular immune response towards the infected cells, and can directly kill infected glioma cells by cell 
lysis. These features absent in other vehicles for gene delivery have made viruses one of the most 
valuable tools for gene therapy of GBM.  
On  the  other  hand,  viral  carriers  and  oncolytic  viruses  still  face  considerable  challenges  for 
successful long-term therapeutic effects. A major difficulty is the limited spread and persistence of the 
virus in the tumor tissue, caused by factors such as low efficiency of initial infection, rapid clearance 
of the viral particles by innate immune cells, and physical barriers that limit particle dispersion [123]. 
Some of these challenges are being actively addressed through strategies involving viral engineering 
and  combination  with  other  antitumor  agents.  Major  developments  in  the  field  include  improved  
re-targeting towards GBM-specific receptors [124], combination with drugs that reduce the immune 
response to the virus [125], ―cloaking‖ of the virus inside carrier cells (described in the following 
section), enhanced infusion of viral particles via convection-enhanced delivery, and engineering of 
viruses  to  express  genes  that  facilitate  their  physical  dispersion  [89],  among  others.  As  current 
limitations are overcome, viral-based approaches (alone or combined with conventional therapy) will 
remain a major choice for gene therapy of GBM.  
3. Stem Cell-Based Gene Therapy of GBM 
Together with viruses, cells have been used to deliver genetic material to brain tumors for the past 
twenty years. Indeed, retroviruses themselves were the first genetic payload delivered by cells injected 
into the tumor stroma [18,19]. Examples of successful carriers have included fibroblasts and HEK293 
cells, both used to deliver replicating viruses, suicide genes (HSV-TK), and anti-angiogenic factors in Cancers 2013, 5   1284 
 
 
gliomas [126,127]. A major limitation of these cell types has been their lack of migratory ability inside 
the tumor, a deficiency that was considered a major cause of therapeutic failure in clinical trials of 
viruses and suicide genes delivered by cells [37]. Currently, the most widely employed cellular carriers 
are stem cells (SCs) of neural, mesenchymal or embryonic origin. While SCs have been studied for 
only half as long as viral carriers and only recently reached the clinical stage, they have proved one of 
the most attractive vehicles to combine gene therapy with virotherapy and conventional therapies.  
The importance of SCs is underscored by a fundamental property absent in other delivery vehicles: 
their ability to migrate towards the tumor cells even when injected peripherally [128,129]. This critical 
feature  allows  them,  in  principle,  to  reach  the  disseminated  tumor  cells  that  are  characteristic  of  
GBM  [128].  As  expected,  SCs  have  already  been  extensively  tested  as  vehicles  for  most  of  the 
approaches described  in the  previous  sections: delivery  of suicide genes,  oncolytic viral  particles,  
anti-angiogenic factors, and immune-boosting cytokines, among others. 
3.1. Neural Stem Cells 
Neural  Stem  Cells  (NSCs)  are  multipotent  progenitors  of  the  neural  lineage  with  indefinite  
self-renewal and ability to differentiate into neurons or glial cells [130]. They are not only highly 
adapted to the neural environment and architecture [131] but also share many properties (such as cell 
motility mechanisms [119]) with the elusive glioma stem-like cells. Engineered NSCs were first used 
against gliomas in 2000 to deliver the cytokine IL-4, therefore improving the immune response against 
the  tumor  [132].  Subsequently,  they  have  been  largely  employed  in  two  major  approaches  for 
antitumor gene therapy: as infected carriers of oncolytic viruses or as engineered cells expressing 
therapeutic genes. 
Using NSCs as carriers of oncolytic viruses -which lyse the carrier cell and infect glioma cells- has 
become  an  interesting  approach  with  multiple  possible  advantages  over  the  inoculation  of  viral 
particles: migratory NSCs may deliver the viruses at further distances within the tumor compared to 
virus  alone;  they  can  protect  the  viruses  from  the  host  immunosurveillance;  and  their  own  lysis 
removes them from the host after therapy [133]. Following this rationale, Herrlinger and colleagues 
were  the  first  to  show  the  feasibility  of  using  NSCs  to  carry  conditionally-replicating  HSV  into  
pre-implanted cerebral gliomas [134]. Similar studies were further pursued with CRAds [135,136], 
demonstrating that pre-loading the virus inside NSCs highly enhanced the reach of the virus within the 
tumor as well as its oncolytic efficacy. 
Engineering NSCs to deliver transgenes rather than viruses into the tumor mass has been a more 
common approach, employed with suicide genes and cytokines. Both CDA and HSV-TK (described in 
Section 2.1) have been tested in NSC therapy of GBM (e.g., [128,137,138]) and in all cases the use of 
NSCs has compared favorably against non-migratory cell carriers. NSCs have also been used to carry 
CDA and IFN-beta cDNAs together, boosting the bystander cytotoxicity with immune response against 
the tumor and resulting in better antitumor response compared to CDA alone [139]. CDA-carrying NSCs 
are currently being tested in the first clinical study of feasibility against recurrent high-grade gliomas 
(NIH trial NCT01172964, Table 1).  
A second group of widely tested transgenes have been immune-boosting interleukins such as IL-4, 
IL-12 and IL-23 [132,140,141]. These studies led to two important conclusions: First, NSC-mediated Cancers 2013, 5   1285 
 
 
sustained delivery of interleukins was found more efficient than viral-based delivery in vivo [132] and 
resulted in improved animal survival. Second, the strong cellular immune response against the tumor 
(at least in the case of IL-23) resulted in long-term surviving animals resistant to tumor re-challenge, 
suggesting the possibility of using SC approaches to trigger long-standing antitumor immunity.  
One  important  cytokine  that  has  been  delivered  by  NSCs  in  gliomas  is  the  Tumor  Necrosis  
Factor-Related Apoptosis-Inducing Ligand (TRAIL), which is capable of inducing apoptosis in tumor 
cells with little effect on normal cells. This effect is potentiated in S-TRAIL, a secreted chimeric 
protein combining the extracellular domains of TRAIL and Flt3L (a ligand for Flt3 tyrosine kinase 
receptor)  [142].  NSCs  carrying  S-TRAIL  were  shown  to  migrate  actively  towards  glioma  cells, 
causing bystander cytotoxicity in the tumor and significantly reducing the burden of pre-implanted 
gliomas [143]. Moreover, combination of NSCs-S-TRAIL with adjuvant chemotherapy showed strong 
potentiation  of  the  antitumor  effects  of  temozolomide,  PI-103  (a  PI3K/mTOR  inhibitor),  and 
bortezomib (a proteasome inhibitor) [144–146].  
A third major group of genes delivered by NSCs in glioma models includes anti-angiogenic factors 
such as endostatin [147], thrombospondin-1 [148], and the angiostatic factor PEX [149]. Although 
these factors can impair the migration of normal and tumor cells, all the studies reported that active 
migration of the engineered NSCs towards tumor cells was unaffected. NSCs distributed extensively in 
the tumor stroma, without concomitant proliferation or differentiation, and caused significant reduction 
of tumor growth and microvascular density.  
3.2. Mesenchymal Stem Cells 
Mesenchymal stem cells (MSCs) are non-hematopoietic, adult multipotent stem cells that can be 
isolated from multiple sources (such as bone marrow, adipose and muscle tissue, or peripheral blood), 
and expanded with relative ease in vitro [150]. These cells migrate to sites of injury and inflammation 
and  are  involved  in  tissue  repair.  Since  tumors  behave  as  non-healing,  expanding  wounds,  they 
strongly  attract  MSCs  [151].  Based  on  this  strong  homing  ability,  MSCs  have  been  employed  in 
multiple strategies against tumors, including gliomas [152]. 
As with NSCs, initial studies of MSCs against experimental gliomas involved the overexpression of 
a therapeutic cytokine (IL-2), resulting in augmented antitumor effect (compared to MSCs alone) and 
prolongation of animal survival [153]. Due to their easy availability for autologous transplantation, 
MSCs have become a very attractive alternative to NSCs towards clinical studies, and have already 
been tested to deliver cytokines, suicide genes, antibody chains and viral particles to gliomas. 
Suicide  genes  originally  tested  in  NSCs  have  been  evaluated  in  MSCs  as  well,  including  
HSV-TK  [144],  CDA  [154],  and  HSV-TK  together  with  connexin-43  to  enhance  bystander 
cytotoxicity [145]. MSCs have also been used as vehicle for the suicide gene carboxylesterase [155].  
A combination of MSC-delivered carboxylesterase with the prodrug CPT-11 (Irinotecan) was tested in 
experimental  brainstem  gliomas  and  showed  effective  conversion  of  the  prodrug but  only  modest 
improvement in animal survival. 
In addition to MSC-delivered IL-2, more recent animal studies have used transduced MSCs to 
deliver IL-7 [156], IL-12 [157], or IL-18 [158] in glioma xenografts. Strong cellular immune response 
was observed following infiltration of the MSCs in the tumor stroma, and resistance of the surviving Cancers 2013, 5   1286 
 
 
animals to tumor re-challenge was observed in the studies using IL-12 and IL-18. MSCs have also 
been used to deliver TRAIL constructs, including a shortened form of secretable TRAIL [159] as well as 
the recombinant TRAIL-Flt3L fusion (S-TRAIL) [160]. Newer studies have combined MSC-delivered 
TRAIL with radiotherapy [161] and with the anti-inflammatory compound MK886 [162], demonstrating 
in both cases synergism compared to MSC-TRAIL alone.  
Finally, the use of MSCs as carriers of conditionally-replicating oncolytic viruses such as CRAds 
has shown that MSCs are capable of suppressing the humoral immune response against the virus, 
resulting in increased persistence of the viral particles [163]. However, MSCs were found less efficient 
than  NSCs  to  deliver  the  same  CRAd  in  orthotopic  xenografts  and  had  lesser  impact  on  animal 
survival  [164].  Nevertheless,  considerable  interest  remains  in  the  use  of  MSCs  to  deliver  those 
oncolytic viruses that have reached clinical trials, such as Ad5Delta24-RGD described in Section 2.5. 
MSCs carrying Ad5Delta24-RGD and injected in the peripheral circulation have been shown to reach 
intracranial gliomas and inhibit tumor growth [165]. Current trends suggest that, if clinical trials with 
the viruses are promising, the use of SCs to carry them into the tumor could be the next step to 
improve their therapeutic efficacy.  
3.3. Embryonic Stem Cells 
Embryonic stem cells (ESCs) are pluripotent cells that form the inner cell mass of the blastocyst 
during gestation and have unlimited proliferative capacity [166]. Difficulties in obtaining and culturing 
these cells—both technical and derived from current legislation on SCs—have made their use much 
more limited than NSC or MSC counterparts, with experiments largely focused on cytokine delivery  
to gliomas. 
The  first  experiments  with  mouse  ESCs  involved  engineering  to  express  TRAIL,  followed  by 
differentiation  into  astrocytes  using  defined  culture  conditions.  ESC-derived  astrocytes  enhanced 
apoptosis of co-cultured glioma cells compared to TRAIL alone [167]. Further experiments demonstrated 
that injection of ESC-derived astrocytes carrying TRAIL could induce severe necrosis in xenografted 
tumors [168], but no survival studies were pursued. Additional in vitro studies using ESC-derived 
astrocytes  demonstrated  that  delivery  of  a  different  cytokine  (IL-24)  also  increased  apoptosis  of  
co-cultured glioma cells and potentiated the effects of radiation and temozolomide [169].  
Human ESC lines have more recently been used to derive NSCs and MSCs, which have been 
subsequently transduced to deliver the suicide gene HSV-TK [170,171]. The goal of these experiments 
was to show the successful conversion of ESCs into cells known to have strong tropism for gliomas, 
and  in  addition  these  studies  demonstrated  successful  targeting  of  intracranial  tumor  burden  and 
extension of animal survival.  
3.4. Advantages and Challenges of Cell-Based Gene Therapy 
The  use  of  SCs  as  gene-delivery  vehicles  is  supported  by  two  unmatched  advantages  when 
compared to passive methods of gene delivery: (a) migratory ability that allows them to infiltrate the 
tumor mass, reaching poorly vascularized areas and the remote borders of the tumor; and (b) strong 
tropism that attracts them towards glioma cells even when injected peripherally, coupled with ability to 
cross  the  blood  brain  barrier.  These  two  features  of  SCs,  added  to  the  possibility  of  performing Cancers 2013, 5   1287 
 
 
extensive genetic engineering to convert them in carriers of multiple transgenes or whole viral vectors, 
make them a versatile tool that can be combined with conventional therapy and additional molecular 
therapy to deliver a large, complex payload inside the tumor. 
However, despite their ability to infiltrate gliomas, SCs are essentially neutral and do not have an 
effect on the tumor unless engineered as gene-delivery vehicles. Since the transgenes are expressed in 
SCs immediately after transduction (in contrast to viral-carried genes, which are expressed only after 
infection of the target cells), a first and considerable technical challenge is to ensure that the SCs will 
survive for as long as it takes to impact the tumor cells, without dying first due to effects of suicide 
genes or oncolytic viruses [172]. Rapid and efficient delivery to the tumor is therefore a critical factor 
when SCs are introduced peripherally. Intravenous injection has been the most common route for 
peripheral introduction of SCs but its efficiency is limited, with less than 2% of the inoculated cells 
colonizing  the  tumor  [173].  A  recent  alternative  has  used  intranasal  inoculation  of  NSCs,  with  a 
delivery efficiency estimated to be as high as 24% [174]. Additional challenges stem from the choice 
of SCs in terms of convenience, permanence in the tumor, and therapeutic efficacy. For example, while 
MSCs  are  easiest  to  obtain  for  autologous  therapy,  there  is  active  discussion  about  their  relative 
efficacy  compared  to NSCs  for different gene-therapy  strategies  [164]. ESCs  present, in  addition, 
ethical and regulatory issues for collection and will likely be replaced by induced pluripotent SCs in  
the future.  
A final and considerable factor that must be addressed with SCs is their safety when introduced in 
the highly aggressive, cytokine- and growth factor-rich environment of the tumor. To this day studies 
have shown that none of the different types of SCs employed in animal models suffered neoplastic 
transformation. However, previous studies have demonstrated that normal neural progenitor cells can 
contribute significantly to the heterogeneous total mass of PDGF-induced malignant gliomas [175]. 
Therefore,  a  desirable  feature  in  future  SC-based  approaches  would  be  the  possibility  of  
selectively eliminating the SCs (e.g., using an inducible suicide gene) after they have reached their 
therapeutic endpoint.  
Overall,  SC-based  gene  therapy  of  GBM  offers  enormous  promise  and,  considering  that  SCs  
have  become  the  choice  carrier  in  other  neuropathologies,  is  likely  to  become  the  fundamental 
component of future combinatorial strategies using gene delivery, molecular-targeting therapy and 
conventional chemoradiotherapy.  
4. Nanotechnology-Based Gene Therapy of GBM 
The  use  of  nanotechnology,  i.e.,  manipulation  of  sub-micron-sized  materials,  to  target  genetic 
material into tumor cells is a relatively novel strategy that remains largely experimental. The only 
nanocarriers that have reached the clinical stage in glioma have been liposomes [9,176], which have 
long been used as carriers for small molecules in glioma and other cancers. Most nanotechnological 
approaches  for  gene  therapy  have  focused  in  optimizing  the  DNA-carrying  vehicles  for  effective 
targeting of tumor cells [177,178], testing many of the same candidate genes used with viruses and 
SCs.  Vehicles that have  been  recently tested in pre-clinical  models  include  novel  formulations  of 
cationic liposomes, nanoparticles, and dendrimers, among others.  
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4.1. Liposomes 
Liposomes are artificial, lipid-based microvesicles usually employed to deliver drugs, peptides and 
proteins into cells. However, chemical engineering of the lipids also permits the formation of stable 
DNA-lipid associations that can be exploited to use liposomes as a gene-delivery vehicle. Following 
this concept, a liposomal vector was devised in the early 2000s to carry a plasmid coding for HSV-TK, 
which was given to patients with recurrent GBM in a phase I/II trial via intratumoral infusion [179], 
followed by administration of the prodrug ganciclovir during 14 days. Radiographic response was 
observed in most patients in this clinical trial, ranging from focal effects to 50% reduction in tumor 
volume, without major adverse events. 
Cationic liposomes have also been used to transfer cytokine genes into glioma cells. A phase I/early 
phase II clinical trial demonstrated the safety and efficacy of this approach to deliver a plasmid coding 
for IFN-beta [180] in patients with recurrent malignant gliomas, following resection of the tumor.  
IFN-beta protein was found in the accumulated fluid in the post-surgical cavity in three out of five 
patients,  for  periods  of  up  to  ten  days  after  injection.  All  patients  showed  positive  radiographic 
response immediately after treatment, although the tumors eventually progressed. A more complex 
liposome  was  recently  devised  to  carry  both  a  therapeutic  gene  (TRAIL)  and  a  cytotoxic  drug 
(paclitaxel), combined with re-targeting via addition of a peptide (angiopep2) that facilitates blood 
brain barrier crossing. This liposome preparation effectively delivered TRAIL to glioma cells in vitro 
even when protected behind a barrier of normal epithelial cells [181]. More importantly, peripherally 
delivered  angiopep2-liposomes  reached  intracranially  xenografted  gliomas  in  mice,  causing  local 
apoptosis in the tumor and extending animal survival.  
Other liposomal preparations have modified not only the surface of the vesicle but also its carrier 
core. For example, magnetite-core cationic liposomes respond to alternating magnetic fields generating 
heat. This effect can be used to activate a heat-shock sensitive promoter in the DNA carried by the 
liposome,  thus  regulating  expression  of  the  therapeutic  gene  [182].  Using  this  strategy,  Ito  and 
colleagues  injected  paramagnetic  liposomes  carrying  TNF-alpha  under  control  of  the  heat-inducible 
promoter  gadd153  into  subcutaneous  gliomas  implanted  in  nude  mice  [183].  Their  results  
showed  heat-regulated  expression  of  TNF-alpha  protein  in  the  tumor  and  subsequent  retardation  of  
glioma growth.  
A  recent  and  ingenious  liposomal  design  used  air-cored  liposomes,  subsequently  loaded  with 
siRNA against the anti-apoptotic protein sirtuin 2 [184]. The liposomes were injected in subcutaneously-
implanted gliomas in nude mice, followed by exposure to brief low-frequency ultrasound. This induced 
cavitation  (bursting)  of  air  bubbles  in  the  liposomal  core,  damaging  neighboring  tumor  cells  and 
enhancing the delivery of therapeutic siRNA. The results demonstrated effective decrease in tumor 
volume and prolonged animal survival when compared to liposomes lacking siRNA or absence of 
ultrasound treatment.  
4.2. Polymers  
Cationic polymers are macromolecules that spontaneously bind DNA via electrostatic interactions. 
This unique property has been used commercially for cell transfection. They offer advantages such as Cancers 2013, 5   1289 
 
 
small size and flexible chemistry that allows extensive modifications to improve biodistribution and 
tumor targeting. 
A  typical  example  of  a  linear  polymer  used  to  deliver  plasmids  or  oligonucleotides  is 
polyethylenimine  (PEI).  This  polymer  binds  DNA  strongly  and  has  high  transfection  efficiency, 
forming small particles that enter the cells via endocytosis [185]. However, in absence  of further 
modifications  it  has  high  cellular  toxicity  and  cannot  reach  intracranial  tumors  when  injected 
peripherally. Chemical engineering of PEI by addition of functional groups such as poly-ethileneglycol 
(PEG) or beta-cyclodextrin has proven sufficient to improve PEI permanence in circulation and in the 
tumor stroma [186]. PEI polymers modified by addition of myristic acid were able to cross the blood 
brain barrier, delivering a TRAIL-coding plasmid to intracranially implanted gliomas and increasing 
survival in tumor-bearing mice [187]. Similarly, PEGylated PEI was re-targeted towards glioma cells 
by chemical addition of an RGD-containing peptide [188]. This polymer (RGD-PEG-PEI) was injected 
intravenously and able to deliver TRAIL cDNA in situ in an intracranial glioma model, increasing 
animal survival. 
In  addition  to  the  chemically  simpler  linear  polymers,  novel  efforts  have  focused  on  using 
repeatedly branched polymers, known as dendrimers, for gene delivery. These molecules offer several 
advantages (such as high surface/volume ratio for DNA binding and well-known chemical behavior) [189] 
that have made them attractive synthetic nanocarriers for gene therapy. A commonly used dendrimer is 
a  hyperbranched  polymer  of  poly-amidoamine  (PAMAM)  characterized  by  biocompatibility, 
controlled biodegradation, low toxicity, and good accumulation in tumors with leaky vasculature [190]. 
A modified version of PAMAM was conjugated with nanoparticle carriers (see next section) and a 
viral Tat-peptide to facilitate cell membrane crossing [191]. This complex polymer (np-PAMAM-Tat) 
was used to deliver anti-EGFR shRNA to subcutaneously-implanted gliomas, inhibiting EGFR/Akt 
signaling  and  slowing  tumor  growth.  Another  modified  version  of  PAMAM  (Arg-PAMAM)  has 
recently  been  used  to  deliver  IFN-beta  cDNA  in  intracranial  glioma  xenografts,  causing  selective 
tumor cell apoptosis and overall tumor shrinkage [192]. 
4.3. Nanoparticles 
As their name indicates, these are nanometer-sized particles that, depending on their size (usually 
ranging from 20 to 50 nm in diameter) may spontaneously cross capillary walls and be endocytosed by 
cells. They have a rigid polymer core and a multi-functionalized surface that has been engineered to 
enhance  DNA  binding,  particle  diffusion,  and  cell-membrane  crossing  [193].  The  core  of  the 
nanoparticles can also be modified with fluorochromes or metallic iron to facilitate in vivo imaging or 
to make them responsive to magnetic stimuli [194,195].  
Super-paramagnetic iron oxide nanoparticles (SPIONs) have been used for delivery of therapeutic 
agents  to  the  CNS  while  being  at  the  same  time  tracked  via  magnetic  resonance  imaging  [196].  
In  a  recent  study,  SPIONs  were  covalently  bound  to  the  capsid  of  an  RGD-targeted  adenovirus 
(replication-deficient  Ad5/3-RGD)  and  used  to  track  the  delivery  of  the  virus  [197].  Results 
demonstrated that viral infectivity of glioma cells was not affected by the SPIONs and that the virus 
could be tracked in a large (porcine) brain, but no studies were performed with gliomas in vivo.  Cancers 2013, 5   1290 
 
 
More complex version of SPIONs have used magnetic nanoparticles simultaneously functionalized 
on  their  surface  with  PEG  (to  bypass  the  blood  brain  barrier),  chitosan  (to  improve  half-life  in 
circulation),  PEI  (to  adsorb  the  therapeutic  DNA)  and  chlorotoxin,  a  re-targeting  peptide  against 
glioma cells [198,199]. These multifunctional SPIONs have been used to demonstrate proof-of-principle 
delivery of siRNA and marker cDNA (eGFP) to glioma cells and subcutaneously-implanted gliomas. 
4.4. Advantages and Challenges of Nanocarrier-Based Gene Therapy 
Being completely synthetic, nanocarriers offer strong advantages as vehicles for gene therapy of 
GBM: size, structure and chemical composition of the carrier can be accurately tailored to enhance 
biodistribution, low toxicity, and optimal cell penetrance. The size of the DNA that can be carried is 
not as limited as in biological carriers, does not require prior genetic engineering of the carrier, and 
allows  in  principle  any  combination  of  plasmids  and  oligonucleotides  as  desired.  The  surface  of 
nanocarriers  is  based  on  well-studied  polymers  that  are  biocompatible,  biodegradable,  and  do  not 
induce  immune  responses  against  the  vehicle,  as  it  is  common  when  using  viral  carriers.  As  an 
additional advantage, the core of the carrier can also be optimized to track it using fluorescence or 
magnetic resonance, a property that would require additional modifications in viral or cell-based carriers.  
On the negative side, the major disadvantage of nanocarriers is that they are completely passive 
vehicles for gene delivery and their efficacy depends on the physical and chemical properties of the 
materials used to build them. Nanocarriers do not migrate actively and do not have neurotropism or 
even cell-specific tropism, therefore the tumor specificity must be ―built from scratch‖ and optimized 
more exhaustively than with SCs or viruses. Their passivity as delivery vehicle also means that their 
distribution in the tumor will be much more limited than that observed with SCs and even with viral 
carriers, which can disperse when they lyse infected tumor cells. Finally, biological effects of novel 
particles and polymers (and their fragments) have not yet been analyzed in long-term studies and the 
overall efficacy of nanocarriers has not been exhaustively compared against other modalities for gene 
delivery. The future of these experimental vehicles for gene therapy of GBM will depend on these 
efficacy studies, using nanocarriers with improved cell type-specificity delivered via convection-enhanced 
delivery and combined with conventional therapies.  
5. Conclusions  
Gene therapy represents today one of the more flexible and robust strategies for adjuvant therapy of 
GBM. As detailed in this review, gene-delivery approaches can be manipulated at multiple levels 
including choice of delivery vehicle, chemical or genetic engineering of the carrier, and selection of 
molecular targets, among others. This wide range of manipulations can be extensively exploited to 
optimize  biodistribution,  persistence,  specificity,  and  targeting  effects  of  the  therapeutic  agents, 
arguably to a much further extension that what can be achieved with improvements in conventional 
chemoradiotherapy. Optimized gene therapy approaches have repeatedly reached the clinical stage:  
A brief query of clinical trials listed by the Journal of Gene Medicine Clinical Trial website [11] and 
trials registered with the US National Institutes of Health [10] reveals, at the time of this writing, over 
a dozen active studies to deliver genetic material in malignant gliomas (Table 1). This underscores the 
extent to which gene therapy has become one of the most important approaches in molecularly-targeted Cancers 2013, 5   1291 
 
 
therapy for GBM, and indicates that future developments in this field will continue improving the 
therapeutic options for this devastating disease.  
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